


ABD957

Cat. No.:	HY-142161		
CAS No.:	3007772-60-0		
Molecular Formula:	C ₂₇ H ₃₆ F ₃ N ₇ O ₅ S		
Molecular Weight:	627.68		
Target:	MAGL		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (39.83 mM; ultrasonic and warming and heat to 60°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	1.5932 mL	7.9658 mL	15.9317 mL
5 mM	0.3186 mL	1.5932 mL	3.1863 mL
10 mM	0.1593 mL	0.7966 mL	1.5932 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC₅₀ of 0.21 μM for ABHD17B. ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells^[1].

IC₅₀ & Target

IC₅₀: 0.21 μM (ABHD17B)^[1]

In Vitro

ABD957 (500 nM; pretreated for 1 h) attenuates N-Ras depalmitoylation in AML cells^[1].
 ABD957 (0.11 nM-10 μM; 72 h) blocks the signaling and proliferation of NRAS-mutant leukemia cells^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
 Cell Proliferation Assay^[1]

Cell Line: OCI-AML3, THP1, HL60, NB-4 and NOMO1 cells

Concentration: 0.1, 1, 10, 100, 1000, 10000 nM

Incubation Time: 72 hours

Result:

Reduced the growth of NRAS-mutant AML cell lines (OCI-AML3, THP1 and HL60), but not KRAS mutant cell lines (NB-4 and NOMO1).

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2023 Oct;10(28):e2302130.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Remsberg JR, et, al. ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. Nat Chem Biol. 2021 Aug;17(8):856-864.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA